A phase II trial of response adapted whole brain radiotherapy after high dose Methotrexate based chemotherapy in patients with newly diagnosed prim...

Date 24 November 2018
Event ESMO Asia 2018 Congress
Session Poster display - Cocktail
Topics Lymphomas
Radiation Oncology
Central Nervous System Malignancies
Presenter Narayan Adhikari
Citation Annals of Oncology (2018) 29 (suppl_9): ix21-ix22. 10.1093/annonc/mdy429
Authors N. Adhikari1, A. Biswas2
  • 1Department Of Radiotherapy And Oncology, All India Institute of Medical Sciences, 110029 - New Delhi/IN
  • 2Department Of Radiation Oncology, All India Institute of Medical Sciences, 110029 - New Delhi/IN



The treatment of primary CNS lymphoma (PCNSL) comprises high dose Methotrexate (HDMTX) based chemotherapy followed by whole brain radiotherapy(WBRT), the major drawback of which is long term neurotoxicity. We intended to assess the feasibility of response adapted WBRT in patients with PCNSL.


We screened 35 patients & enrolled 24 patients with PCNSL in a phase II trial. They underwent 5 two-weekly cycles of MVP chemotherapy with HDMTX, Vincristine & Procarbazine. Rituximab was added in 16 patients as per their preference & affordability. Patients with complete response (CR) to induction chemotherapy were given reduced dose WBRT 23.4Gy/13fractions/2.5weeks while those with partial response (PR), stable or progressive disease(PD) were given standard dose WBRT 45Gy/25fractions/5 weeks. Thereafter 2 cycles of consolidation chemotherapy with Cytarabine was given. The primary endpoints of the study were assessment of response rate & progression free survival (PFS). The secondary endpoints were assessment of overall survival (OS), toxicity profile, serial changes in quality of life & neuropsychological parameters.


The median age at diagnosis was 50 years. Out of 20 patients who completed induction chemotherapy, 10(50%) achieved CR, 9(45%) had PR & 1 patient had PD. After a median follow-up period of 21.05 months, the median OS and PFS had not been reached. The actuarial rates of 3 year PFS & OS were 51% & 51.4% respectively. 4 patients in reduced dose WBRT arm had recurrence & 2 of them died of PD, whereas there was one recurrence and no cancer related death in standard dose WBRT arm. On univariate analysis of PFS, age≤60 years(p = 0.004) & use of standard dose WBRT (p = 0.047) led to significantly improved outcome. Serial neuropsychological assessments showed marked improvement in general cognition, verbal fluency & motor speed after induction chemotherapy & treatment completion.


In patients with newly diagnosed PCNSL, reduced dose WBRT after CR to HDMTX based chemotherapy may lead to suboptimal clinical outcome due to higher risk of recurrence, progression & early death.

Editorial acknowledgement

Clinical trial identification

Clinical Trial Registry India: CTRI/2015/10/006268.

Legal entity responsible for the study

The authors.


All India Institute of Medical Sciences, New Delhi, Indian Council of Medical Research.


All authors have declared no conflicts of interest.